Concord Drugs Limited (BOM:538965)

Concord Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	450.74	452.45	449.25	520.81	589.57	513.57
Other Revenue	0	0	-	-	0.86	0.87
Revenue	450.74	452.45	449.25	520.81	590.43	514.44
Revenue Growth (YoY)	-14.11%	0.71%	-13.74%	-11.79%	14.77%	0.03%
Cost of Revenue	356.08	356.47	337.33	415.96	425.7	434.11
Gross Profit	94.66	95.98	111.92	104.85	164.73	80.33
Selling, General & Admin	42.23	46.35	60.76	49.19	48.91	37.55
Other Operating Expenses	7.01	8.29	10.73	9.94	7.55	9.71
Operating Expenses	63.79	68.94	87.04	75.38	125.59	60.92
Operating Income	30.86	27.04	24.87	29.46	39.14	19.41
Interest Expense	-19.78	-19.19	-18.17	-16.34	-15.79	-13.31
Interest & Investment Income	0.14	0.14	0.09	0.06	0.12	0.08
Other Non Operating Income (Expenses)	-1.08	-1.08	-0.5	-0.7	-0.99	-0.89
EBT Excluding Unusual Items	10.14	6.91	6.29	12.49	22.48	5.29
Other Unusual Items	-	-	-	-	-	37.63
Pretax Income	10.14	6.91	6.29	12.49	22.48	42.92
Income Tax Expense	4.39	3.55	1.57	2.63	6.54	10.1
Net Income	5.76	3.36	4.72	9.86	15.94	32.82
Net Income to Common	5.76	3.36	4.72	9.86	15.94	32.82
Net Income Growth	-	-28.82%	-52.08%	-38.19%	-51.42%	899.60%
Shares Outstanding (Basic)	10	10	10	9	9	9
Shares Outstanding (Diluted)	10	10	10	9	9	9
Shares Change (YoY)	-4.27%	-	7.35%	6.53%	-	-
EPS (Basic)	0.58	0.34	0.47	1.06	1.82	3.75
EPS (Diluted)	0.58	0.34	0.47	1.06	1.82	3.75
EPS Growth	-	-28.47%	-55.57%	-41.87%	-51.47%	898.78%
Free Cash Flow	42.28	13.89	-2.26	8.06	-16.82	-36.74
Free Cash Flow Per Share	4.25	1.39	-0.23	0.87	-1.92	-4.20
Gross Margin	21.00%	21.21%	24.91%	20.13%	27.90%	15.62%
Operating Margin	6.85%	5.98%	5.54%	5.66%	6.63%	3.77%
Profit Margin	1.28%	0.74%	1.05%	1.89%	2.70%	6.38%
Free Cash Flow Margin	9.38%	3.07%	-0.50%	1.55%	-2.85%	-7.14%
EBITDA	45.41	41.34	40.43	45.72	56.79	33.06
EBITDA Margin	10.08%	9.14%	9.00%	8.78%	9.62%	6.43%
D&A For EBITDA	14.55	14.31	15.55	16.26	17.65	13.65
EBIT	30.86	27.04	24.87	29.46	39.14	19.41
EBIT Margin	6.85%	5.98%	5.54%	5.66%	6.63%	3.77%
Effective Tax Rate	43.26%	51.37%	24.89%	21.09%	29.08%	23.54%
Revenue as Reported	450.81	452.59	449.34	520.89	590.57	514.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.